Page 1

vaccitech Vaccitech Reports Third Quarter 2021 Financial Results and Recent Corporate Developments November 12 , 2021 OXFORD , United Kingdom , Nov. 12 , 2021 ( GLOBE NEWSWIRE ) -- Vaccitech plc ( NASDAQ : VACC ) today announced its financial results for the third quarter , ended September 30 , 2021 , and provided an overview of the Company's recent corporate developments . Vaccitech is a clinical - stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer . " We continue to advance our promising pipeline with the recent publication of data on our MERS vaccine program . We also anticipate that initial clinical data on two of our chronic infectious disease therapeutic programs will be presented at scientific conferences next week , " commented Bill Enright , Vaccitech's CEO . " As we continue to expand and advance our programs , we will need additional lab and office space for our talented staff so we have planned a move mid next year into a new , state of the art facility . " Third Quarter and Recent Corporate Developments . Signed a clinical trial collaboration agreement with Arbutus Biopharma Corporation to evaluate an innovative therapeutic combination for the treatment of subjects with chronic hepatitis B virus infection ( CHB ) who are already receiving standard- of - care nucleoside or nucleotide analog ( NA ) therapy . The Phase 2a clinical trial will evaluate the safety , pharmacokinetics , immunogenicity , and antiviral activity of Arbutus's RNAi therapeutic , AB - 729 , followed by the Company's immunotherapy candidate , VTP - 300 , in NA - suppressed subjects with CHB . • Preclinical research demonstrated that VTP - 600 , a ChAdOx1 / MVA prime - boost immunotherapeutic , demonstrated potential as an anti - cancer therapeutic . The research was conducted by scientists at the University of Oxford and the Ludwig Institute for Cancer Research . • Signed a lease for 31,000 square feet within the Zeus development at Harwell Science and Innovation Campus . The site will house the Company's headquarters , state - of - the - art wet laboratory and offices . Vaccitech anticipates completing the relocation by mid - 2022 . • Announced online publication in The Lancet Microbe of the results of a Phase 1 clinical trial of VTP - 500 , a vaccine candidate in development to prevent Middle East Respiratory Syndrome ( MERS ) . The study , conducted by researchers at The King Abdullah International Medical Research Centre and Oxford University , showed that the vaccine candidate was generally well tolerated and induced both humoral and cellular immune responses . Upcoming Milestones • At the virtual AASLD's The Liver MeetingⓇ in November , two posters will present safety and immunogenicity data from the Phase 1 and Phase 1b / 2a trials of VTP - 300 : HBV001 , in healthy volunteers and patients with chronic hepatitis B ( CHB ) infection and HBV002 in patients with CHB infection . The posters become available for viewing by attendees at 8 a.m. EST on November 12 . • At the virtual 34th International Papillomavirus Conference in November , the Company expects to present safety and immunogenicity data from the lead - in portion of the Phase 1 / 2a clinical trial of VTP - 200 . • In the fourth quarter , the Company expects to initiate dosing in a Phase 1 / 2a trial of VTP - 600 in patients with non - small cell lung cancer in combination with a checkpoint inhibitor and chemotherapy . The trial is currently open for enrollment . • In the first quarter of 2022 , the Company intends to conduct an interim efficacy review of HBV002 , the Phase 1b / 2a clinical trial of VTP - 300 in patients with chronic HBV infection . • In the second quarter of 2022 , the Company expects to initiate dosing in a Phase 1 / 2a clinical trial of VTP - 800 / 850 , in combination with a checkpoint inhibitor , in patients with prostate cancer . • In the third quarter of 2022 , the Company intends to conduct an interim efficacy review of HPV001 , a Phase 1 / 2a clinical trial of VTP - 200 , a potential non - invasive treatment for persistent high - risk HPV infection . Third Quarter 2021 Financial Highlights : • Cash position : As of September 30 , 2021 , cash and cash equivalents were $ 233.9 million , compared to $ 43.3 million as of December 31 , 2021. The increase was primarily due to completion of the Series B financing in the first quarter of 2021 , which raised $ 168 million including the conversion of our previously issued convertible loan notes , and to the initial public offering in the second quarter , which raised gross proceeds of $ 110.5 million . The Company believes its cash and cash equivalents are sufficient to fund operations into the first half of 2024 .